Helix BioPharma Appoints Dr. Thomas Mehrling as CEO to Drive Clinical Development Plan
02:54 Share

Helix BioPharma has named Dr. Thomas Mehrling as its new CEO, bringing his extensive experience in pharmaceutical oncology to lead the company's clinical development plan. Dr. Mehrling will focus on achieving clinical milestones and introducing groundbreaking cancer drugs, starting with a Phase II study for non-small cell lung cancer. Chairman Jacek Antas expresses confidence in Dr. Mehrling's leadership and the company's commitment to innovation and rapid decision-making in the fight against cancer.